The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses
are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 cetuximab. Study
treatment continues until disease progression or unacceptable toxicity (ie, not for a fixed
number of courses). The primary endpoint of the study is progression-free survival (PFS) time
according to RECIST 1.0; key secondary endpoints include overall survival (OS) time, overall
response rate (ORR), and safety/tolerability.
Metastatic Colorectal Cancer
Clinical Study Identifier
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.